Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Shares of Dynavax Technologies (NASDAQ:DVAX) surged about 37% on early Wednesday after French drugmaker Sanofi (NASDAQ:SNY) ...

Here are some of the stocks making notable moves in Wednesday's premarket action: Dynavax Technologies stock is up 37% after ...

Sanofi (NASDAQ:SNY) is one of the Best Affordable Stocks to Buy According to Analysts. On December 24, Sanofi (NASDAQ:SNY) ...

The French drugmaker is looking to dealmaking after some experimental drugs missed their goals in clinical studies or were ...

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

Detailed price information for Dynavax Technologies (DVAX-Q) from The Globe and Mail including charting and trades.

Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.

Sanofi acquires Dynavax for $2.2B, gaining Heplisav-B and promising vaccine pipeline. Click here to read my analysis of SNY stock and the DVAX acquisition.

The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which ...

Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult ...